Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Ann Hynes – Mizuho Lisa Gill – JPMorgan Michael Cherny – Leerink Partners Patrick Donnelly – Citi Erin Wright – Morgan Stanley David Westenberg – Piper Sandler Jack Meehan – Nephron Research Pito Chickering – Deutsche Bank Andrew Brackmann – William Blair Kevin Caliendo – UBS Elizabeth Anderson – Evercore ISI Eric Coldwell – Baird Stephanie Davis – Barclays John Kim – Bank of America Operator Good day and thank you for standing by. Welcome to the Q3 2024 Labcorp Holdings Earnings Conference Call.
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates
Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago.
Labcorp beats quarterly estimates on diagnostic test demand
Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.
Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Labcorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
Labcorp Stock Gains From Biopharma Business Amid FX Woe
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Should You Continue to Retain LH Stock in Your Portfolio?
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
